Print

News

  • WHO signs MoU with International Generic and Biosimilar Medicines Association to promote access (October 2019)

    Full access to medicines is hampered by a variety of factors. Two important barriers are high prices and regulatory issues such as long lag times in bringing medicines to market. Read More
  • IGBA recommendations for action to support a sustainable global pharmaceutical market for continued patient access worldwide to safe, effective and high-quality medicines (October 2019)

    IGBA recommendations for action to support a sustainable global pharmaceutical market for continued patient access worldwide to safe, effective and high-quality medicines (October 2019) Read More
  • The positive impact that generic and biosimilar medicines have on patients and health systems (October 2019)

    The positive impact that generic and biosimilar medicines have on patients and health systems (October 2019) Read More
  • Op-ed: Trade agreement drug monopoly is obsolete given faster, better drug discovery

    October 2, 2019. For decades, the brand-name drug industry has relentlessly promoted the message that any reduction in its government-protected monopolies would have detrimental effects on innovation. Members of Congress on both sides of the aisle have taken that message Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site